Acute exacerbations of COPD: The Challenge is Early Treatment

T. Seemungal,J. Wedzicha

DOI: https://doi.org/10.1080/15412550902806011

2009-01-01

Abstract:Approximately 15 million Americans have COPD, leading to an estimated annual direct medical cost of US $15 billion (1). Indirect costs due to morbidity (loss of work time and productivity) and premature mortality were estimated at $32.1 million in 2002 (1). But because COPD may be overlooked as a cause of death these costs may be an underestimate (2) and the total annual cost of COPD using data from the ‘Confronting COPD’ survey has been estimated to be as high as $70 billion in the USA alone (2). The global burden of COPD is huge and by 2020 it is estimated that there will be 3.5 million deaths from COPD worldwide (3). Most of the health burden from COPD arises from hospital admissions in late disease (4). Hospitalisation rates have depended on type of study but range from as low as 0.09 to 2.4 per patient per year (5). In one American study, length of in-patient stay and number of hospital admissions both decreased over a three year period with a commensurate increase in outpatient visits (6). The study also found a 22% decrease in COPD-related total medical costs mainly because of a decrease in the hospital costs for COPD, thus showing that COPD costs can be effectively reduced through decreasing hospitalization (6). Previous studies have shown that hospitalisations are related to poorer quality of life scores (7, 8) and can be reduced through patient-focused interventions such as integrated care (9). Further the interventional arms of the TORCH and UPLIFT studies were associated with a 12 to 18% reduction in the rate of hospitalisations for COPD exacerbations compared to placebo (10, 11). Taken together, these data suggest that hospital admission rates are a suitable measure of health burden in COPD and respond to interventions. Thus factors that are asso-